SermorelinInterpret the evidence
How researchers separated peptide absorption from a hormone response
2 numbered sourcesSource years 1993, 2013
Peptides are short amino-acid chains joined by peptide bonds, and some tell the pituitary to release growth hormone. Sermorelin is an amidated 29-amino-acid fragment of human growth hormone–releasing hormone (GHRH). An early study in volunteers compared how much of this fragment reached blood and how long the downstream hormone response lasted under different experimental conditions. [1, 2]
No recent primary study directly repeating this absorption comparison was identified. The older experiment enrolled 30 healthy men and measured both the GHRH fragment and growth hormone (GH). When the fragment entered directly into the circulation, its blood concentration fell quickly, but growth hormone stayed elevated for longer. In the other study condition, researchers measured low absorption through nasal tissue and observed a hormone response under the particular conditions tested. [1]
The two observations describe separate processes. Absorption describes how much of the compound reaches the circulation. Clearance describes how rapidly it leaves the measured compartment. A downstream response can outlast a circulating signal because cells take time to release a hormone and the released hormone takes time to clear. The time course of GH cannot be read as the time course of sermorelin itself. The amount absorbed is also specific to the formulation and conditions used in the experiment. [1]
The results are specific to the material, comparisons and healthy adult population used in the 1993 experiment. They do not establish the performance of other formulations or a benefit in people with growth hormone deficiency. The research explains why studies often collect both kinds of blood measurements when a peptide is intended to trigger a second biological signal. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.
- 2.U.S. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register (publication 2013-03-04). (opens in a new tab)
govinfo.gov↩ Back to text
